Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof
AssigneePfizer Inc.
InventorsRoger B. Ruggeri, George T. Magnus-Aryitey, Benjamin Aaron Thuma
Life of this patent
Estimating the term…
Abstract
Compounds of Formula (I) that act as antagonists at the mu, kappa and/or delta opioid receptors and therefore useful in the treatment of diseases, conditions and/or disorders that benefit from such antagonism in animals are described herein. where R, R1, R2a, R2b, R3, R4, V, R6, R7, R8, R9, W and X are described herein.
Claims5
1-45. (canceled)
The compound 3′,5′-difluoro-2-methyl-4′-[(3-methyl-butylamino)-methyl]-biphenyl-4-carboxylic acid amide;
- or a pharmaceutically acceptable salt, hydrate, or hydrate salt thereof.
A pharmaceutical composition comprising a therapeutically effective amount of the compound 3′,5′-difluoro-2-methyl-4′-[(3-methyl-butylamino)-methyl]-biphenyl-4-carboxylic acid amide, or a pharmaceutically acceptable salt, hydrate, or hydrate salt thereof, with or without one or more pharmaceutically acceptable excipients, diluents, or carriers.
A method for treating obesity or inhibiting weight gain comprising administering to an animal in need thereof an effective amount of 3′,5′-difluoro-2-methyl-4′-[(3-methyl-butylamino)-methyl]-biphenyl-4-carboxylic acid amide, or a pharmaceutically acceptable salt, hydrate, or hydrate salt thereof, with or without one or more pharmaceutically acceptable excipients, diluents, or carriers.
Dependencies are inferred from the claim text.